The OncoAlert Network 🚨
@oncoalert.bsky.social
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨
www.OncoAlert360.com
www.OncoAlert360.com
Pinned
Colleagues, the Complete #ESMO25 OncoAlert Newsletter is coming Oct 27‼️ GET IT HERE👉 oncoalert.m-pages.com/nhMpwe/oncoa...
50 of our PICKS of TOP Trials out of Berlin 🇩🇪
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social
50 of our PICKS of TOP Trials out of Berlin 🇩🇪
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social
The OncoAlert 🚨TOP STACK: MATTERHORN
Durvalumab combined with standard FLOT chemotherapy has received US 🇺🇸approval for treating adults with resectable, early to locally advanced gastric and gastroesophageal junction cancers, based on the MATTERHORN
Durvalumab combined with standard FLOT chemotherapy has received US 🇺🇸approval for treating adults with resectable, early to locally advanced gastric and gastroesophageal junction cancers, based on the MATTERHORN
November 26, 2025 at 5:59 PM
The OncoAlert 🚨TOP STACK: MATTERHORN
Durvalumab combined with standard FLOT chemotherapy has received US 🇺🇸approval for treating adults with resectable, early to locally advanced gastric and gastroesophageal junction cancers, based on the MATTERHORN
Durvalumab combined with standard FLOT chemotherapy has received US 🇺🇸approval for treating adults with resectable, early to locally advanced gastric and gastroesophageal junction cancers, based on the MATTERHORN
ASSOCIATION BETWEEN TYPE AND LOCATION OF GERMLINE BRCA1/2 PATHOGENIC OR LIKELY PATHOGENIC VARIANTS WITH PHENOTYPE AND PROGNOSIS IN YOUNG PATIENTS WITH BREAST CANCER: RESULTS FROM AN INTERNATIONAL COHORT STUDY
www.annalsofoncology.org/article/S092...
www.annalsofoncology.org/article/S092...
November 26, 2025 at 4:28 PM
ASSOCIATION BETWEEN TYPE AND LOCATION OF GERMLINE BRCA1/2 PATHOGENIC OR LIKELY PATHOGENIC VARIANTS WITH PHENOTYPE AND PROGNOSIS IN YOUNG PATIENTS WITH BREAST CANCER: RESULTS FROM AN INTERNATIONAL COHORT STUDY
www.annalsofoncology.org/article/S092...
www.annalsofoncology.org/article/S092...
FDA Approval for durvalumab combined with FLOT in #GastricCancer
Based on MATTEHORN
Source: AstraZeneca
www.astrazeneca.com/media-centre...
Durvalumab combined wi/ FLOT chemotherapy has received US approval for treating adults with resectable, early to locally advanced gastric and GEJ cancers
Based on MATTEHORN
Source: AstraZeneca
www.astrazeneca.com/media-centre...
Durvalumab combined wi/ FLOT chemotherapy has received US approval for treating adults with resectable, early to locally advanced gastric and GEJ cancers
November 25, 2025 at 7:29 PM
FDA Approval for durvalumab combined with FLOT in #GastricCancer
Based on MATTEHORN
Source: AstraZeneca
www.astrazeneca.com/media-centre...
Durvalumab combined wi/ FLOT chemotherapy has received US approval for treating adults with resectable, early to locally advanced gastric and GEJ cancers
Based on MATTEHORN
Source: AstraZeneca
www.astrazeneca.com/media-centre...
Durvalumab combined wi/ FLOT chemotherapy has received US approval for treating adults with resectable, early to locally advanced gastric and GEJ cancers
MEDiscussion at #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org/events/medtalk
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
November 24, 2025 at 7:17 PM
MEDiscussion at #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org/events/medtalk
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
FDA🇺🇸 approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive #BladderCancer
www.fda.gov/drugs/resour...
The approval is based on the phase 3 KEYNOTE-905/EV-303 trial, which randomized 344 patients to perioperative pembrolizumab plus enfortumab vedotin versus immediate surgery
www.fda.gov/drugs/resour...
The approval is based on the phase 3 KEYNOTE-905/EV-303 trial, which randomized 344 patients to perioperative pembrolizumab plus enfortumab vedotin versus immediate surgery
November 21, 2025 at 6:19 PM
FDA🇺🇸 approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive #BladderCancer
www.fda.gov/drugs/resour...
The approval is based on the phase 3 KEYNOTE-905/EV-303 trial, which randomized 344 patients to perioperative pembrolizumab plus enfortumab vedotin versus immediate surgery
www.fda.gov/drugs/resour...
The approval is based on the phase 3 KEYNOTE-905/EV-303 trial, which randomized 344 patients to perioperative pembrolizumab plus enfortumab vedotin versus immediate surgery
Improving equitable access to comprehensive care for people with advanced breast cancer: a global expert review and call-to-action for 2025–2035
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
November 19, 2025 at 4:40 PM
Improving equitable access to comprehensive care for people with advanced breast cancer: a global expert review and call-to-action for 2025–2035
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉 buff.ly/QJgM3QV
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer #KidneyCancer
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer #KidneyCancer
November 19, 2025 at 4:14 PM
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉 buff.ly/QJgM3QV
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer #KidneyCancer
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer #KidneyCancer
NEWS FROM INDUSTRY
UPDATE: lidERA Trial In #BreastCancer
Source: Roche
www.roche.com/media/releas...
Roche announced that its phase III lidERA study of the investigational SERD giredestrant in ER-positive, HER2-negative early-stage breast cancer met its primary endpoint at an interim analysis
UPDATE: lidERA Trial In #BreastCancer
Source: Roche
www.roche.com/media/releas...
Roche announced that its phase III lidERA study of the investigational SERD giredestrant in ER-positive, HER2-negative early-stage breast cancer met its primary endpoint at an interim analysis
November 18, 2025 at 5:02 PM
NEWS FROM INDUSTRY
UPDATE: lidERA Trial In #BreastCancer
Source: Roche
www.roche.com/media/releas...
Roche announced that its phase III lidERA study of the investigational SERD giredestrant in ER-positive, HER2-negative early-stage breast cancer met its primary endpoint at an interim analysis
UPDATE: lidERA Trial In #BreastCancer
Source: Roche
www.roche.com/media/releas...
Roche announced that its phase III lidERA study of the investigational SERD giredestrant in ER-positive, HER2-negative early-stage breast cancer met its primary endpoint at an interim analysis
Our @oncoalert.bsky.social 🚨Faculty Biagio Ricciuti 🇺🇸with his TOP picks of #LungCancer 🫁 WATCH HERE 👉 www.youtube.com/watch?v=eRIS...
#ESMO25
#ESMO25
TOP3 Hightlights in #LungCancer from #ESMO25
YouTube video by OncoAlert 360
www.youtube.com
November 18, 2025 at 4:36 PM
Our @oncoalert.bsky.social 🚨Faculty Biagio Ricciuti 🇺🇸with his TOP picks of #LungCancer 🫁 WATCH HERE 👉 www.youtube.com/watch?v=eRIS...
#ESMO25
#ESMO25
Join @Achard_Verane and @BertrandTOMBAL for this Manuscript2Practice series on postoperative #ProstateCancer recurrence ⭐️WATCH HERE👉 mirrorsmed.org/m2p-postoper...
brought to you by our collaborators at @mirrorsmed
brought to you by our collaborators at @mirrorsmed
November 17, 2025 at 4:25 PM
Join @Achard_Verane and @BertrandTOMBAL for this Manuscript2Practice series on postoperative #ProstateCancer recurrence ⭐️WATCH HERE👉 mirrorsmed.org/m2p-postoper...
brought to you by our collaborators at @mirrorsmed
brought to you by our collaborators at @mirrorsmed
DAY Three #CFS25 🚨
A sea change in Small Cell Lung Cancer (SCLC) treatment is here! Dr. Charles Rudin discusses the shift from traditional chemo to novel agents like bispecific T-cell engagers & ADCs #SCLC #LungCancer
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
A sea change in Small Cell Lung Cancer (SCLC) treatment is here! Dr. Charles Rudin discusses the shift from traditional chemo to novel agents like bispecific T-cell engagers & ADCs #SCLC #LungCancer
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
November 14, 2025 at 8:07 PM
DAY Three #CFS25 🚨
A sea change in Small Cell Lung Cancer (SCLC) treatment is here! Dr. Charles Rudin discusses the shift from traditional chemo to novel agents like bispecific T-cell engagers & ADCs #SCLC #LungCancer
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
A sea change in Small Cell Lung Cancer (SCLC) treatment is here! Dr. Charles Rudin discusses the shift from traditional chemo to novel agents like bispecific T-cell engagers & ADCs #SCLC #LungCancer
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
DAY Three of #CFS25 🚨
Stage I-III cancer management is evolving! Dr. Thomas Marron discusses how neoadjuvant and perioperative immunotherapy are now demonstrating a significant OS benefit by targeting micrometastatic disease.
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Stage I-III cancer management is evolving! Dr. Thomas Marron discusses how neoadjuvant and perioperative immunotherapy are now demonstrating a significant OS benefit by targeting micrometastatic disease.
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
November 14, 2025 at 6:55 PM
DAY Three of #CFS25 🚨
Stage I-III cancer management is evolving! Dr. Thomas Marron discusses how neoadjuvant and perioperative immunotherapy are now demonstrating a significant OS benefit by targeting micrometastatic disease.
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Stage I-III cancer management is evolving! Dr. Thomas Marron discusses how neoadjuvant and perioperative immunotherapy are now demonstrating a significant OS benefit by targeting micrometastatic disease.
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
DAY Three #CFS25 🚨
Incredible progress in MSI-H localized colorectal cancer! Dr. Andrea Cercek's work shows that 82% of non-rectal tumors achieved a clinical complete response with systemic immunotherapy. #ColorectalCancer
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Incredible progress in MSI-H localized colorectal cancer! Dr. Andrea Cercek's work shows that 82% of non-rectal tumors achieved a clinical complete response with systemic immunotherapy. #ColorectalCancer
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
November 14, 2025 at 3:10 PM
DAY Three #CFS25 🚨
Incredible progress in MSI-H localized colorectal cancer! Dr. Andrea Cercek's work shows that 82% of non-rectal tumors achieved a clinical complete response with systemic immunotherapy. #ColorectalCancer
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Incredible progress in MSI-H localized colorectal cancer! Dr. Andrea Cercek's work shows that 82% of non-rectal tumors achieved a clinical complete response with systemic immunotherapy. #ColorectalCancer
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Day Three #CFS25 🚨
Precision medicine is transforming GI oncology! Dr. Rona Yaeger dives into targeted strategies for BRAF, KRAS, and HER2 across colorectal, biliary tract, esophageal, and pancreatic cancers, #GIOncology
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Precision medicine is transforming GI oncology! Dr. Rona Yaeger dives into targeted strategies for BRAF, KRAS, and HER2 across colorectal, biliary tract, esophageal, and pancreatic cancers, #GIOncology
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
November 14, 2025 at 2:30 PM
Day Three #CFS25 🚨
Precision medicine is transforming GI oncology! Dr. Rona Yaeger dives into targeted strategies for BRAF, KRAS, and HER2 across colorectal, biliary tract, esophageal, and pancreatic cancers, #GIOncology
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Precision medicine is transforming GI oncology! Dr. Rona Yaeger dives into targeted strategies for BRAF, KRAS, and HER2 across colorectal, biliary tract, esophageal, and pancreatic cancers, #GIOncology
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer #KidneyCancer
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer #KidneyCancer
November 13, 2025 at 3:55 PM
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer #KidneyCancer
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer #KidneyCancer
DAY Two of #CFS25 🚨
Dr. Vincent Xu breaks down the latest in combination therapy for Renal Cell Carcinoma (RCC). PD-1 based doublets are the standard of care for 1st-line metastatic disease. #KidneyCancer #RCC #CombinationTherapy
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0
Dr. Vincent Xu breaks down the latest in combination therapy for Renal Cell Carcinoma (RCC). PD-1 based doublets are the standard of care for 1st-line metastatic disease. #KidneyCancer #RCC #CombinationTherapy
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0
November 13, 2025 at 2:55 PM
DAY Two of #CFS25 🚨
Dr. Vincent Xu breaks down the latest in combination therapy for Renal Cell Carcinoma (RCC). PD-1 based doublets are the standard of care for 1st-line metastatic disease. #KidneyCancer #RCC #CombinationTherapy
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0
Dr. Vincent Xu breaks down the latest in combination therapy for Renal Cell Carcinoma (RCC). PD-1 based doublets are the standard of care for 1st-line metastatic disease. #KidneyCancer #RCC #CombinationTherapy
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0
Day One of #CFS25 🚨
Should we treat Clonal Hematopoiesis (CH)? Dr. Uma Borate explores refining treatment goals for CHIP and Lower-Risk MDS, noting that CH mutations offer a potential 'window for early intervention' before progression to AML. #MDS #CHIP #Leukemia #Hematology
Should we treat Clonal Hematopoiesis (CH)? Dr. Uma Borate explores refining treatment goals for CHIP and Lower-Risk MDS, noting that CH mutations offer a potential 'window for early intervention' before progression to AML. #MDS #CHIP #Leukemia #Hematology
November 12, 2025 at 8:05 PM
Day One of #CFS25 🚨
Should we treat Clonal Hematopoiesis (CH)? Dr. Uma Borate explores refining treatment goals for CHIP and Lower-Risk MDS, noting that CH mutations offer a potential 'window for early intervention' before progression to AML. #MDS #CHIP #Leukemia #Hematology
Should we treat Clonal Hematopoiesis (CH)? Dr. Uma Borate explores refining treatment goals for CHIP and Lower-Risk MDS, noting that CH mutations offer a potential 'window for early intervention' before progression to AML. #MDS #CHIP #Leukemia #Hematology
Day One of #CFS25 🚨
Big changes in CLL management! Dr. John Allan reviews the latest NCCN Guideline updates, fixed-duration doublets and triplets, and overcoming resistance to BTK inhibitors.
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Big changes in CLL management! Dr. John Allan reviews the latest NCCN Guideline updates, fixed-duration doublets and triplets, and overcoming resistance to BTK inhibitors.
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
November 12, 2025 at 3:40 PM
Day One of #CFS25 🚨
Big changes in CLL management! Dr. John Allan reviews the latest NCCN Guideline updates, fixed-duration doublets and triplets, and overcoming resistance to BTK inhibitors.
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Big changes in CLL management! Dr. John Allan reviews the latest NCCN Guideline updates, fixed-duration doublets and triplets, and overcoming resistance to BTK inhibitors.
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Day One of #CFS25
Now with When should we use CAR-T for early relapsed Multiple Myeloma (RRMM)?
Dr. Noa Biran highlights that unprecedented efficacy, healthier T-cells, and improved quality of life favor early CAR-T, especially for high-risk disease. #MultipleMyeloma #CARTcell #Oncology
Now with When should we use CAR-T for early relapsed Multiple Myeloma (RRMM)?
Dr. Noa Biran highlights that unprecedented efficacy, healthier T-cells, and improved quality of life favor early CAR-T, especially for high-risk disease. #MultipleMyeloma #CARTcell #Oncology
November 12, 2025 at 2:55 PM
Day One of #CFS25
Now with When should we use CAR-T for early relapsed Multiple Myeloma (RRMM)?
Dr. Noa Biran highlights that unprecedented efficacy, healthier T-cells, and improved quality of life favor early CAR-T, especially for high-risk disease. #MultipleMyeloma #CARTcell #Oncology
Now with When should we use CAR-T for early relapsed Multiple Myeloma (RRMM)?
Dr. Noa Biran highlights that unprecedented efficacy, healthier T-cells, and improved quality of life favor early CAR-T, especially for high-risk disease. #MultipleMyeloma #CARTcell #Oncology
Big News from #APCCC26
You have more time to submit your abstract. 🚨 NEW DEADLINE!
Creating new opportunities for younger investigators in advanced #ProstateCancer
📅 New deadline: 23 November 2025 CET 👉 onlineevent.ch/APCCC/abstra...
🎟️ Registration: onlineevent.ch/APCCC/2026
Silke & Aurelius
You have more time to submit your abstract. 🚨 NEW DEADLINE!
Creating new opportunities for younger investigators in advanced #ProstateCancer
📅 New deadline: 23 November 2025 CET 👉 onlineevent.ch/APCCC/abstra...
🎟️ Registration: onlineevent.ch/APCCC/2026
Silke & Aurelius
November 12, 2025 at 1:39 PM
Big News from #APCCC26
You have more time to submit your abstract. 🚨 NEW DEADLINE!
Creating new opportunities for younger investigators in advanced #ProstateCancer
📅 New deadline: 23 November 2025 CET 👉 onlineevent.ch/APCCC/abstra...
🎟️ Registration: onlineevent.ch/APCCC/2026
Silke & Aurelius
You have more time to submit your abstract. 🚨 NEW DEADLINE!
Creating new opportunities for younger investigators in advanced #ProstateCancer
📅 New deadline: 23 November 2025 CET 👉 onlineevent.ch/APCCC/abstra...
🎟️ Registration: onlineevent.ch/APCCC/2026
Silke & Aurelius
Straight from #UromigosLive 2025
A GREAT discussion on ADC use in #BladderCancer
The possibility of Combination Trials, seeing the trade off between Toxicity and the Long Term Benefit
Complete Video Here x.com/Uromigos/sta...
A GREAT discussion on ADC use in #BladderCancer
The possibility of Combination Trials, seeing the trade off between Toxicity and the Long Term Benefit
Complete Video Here x.com/Uromigos/sta...
November 8, 2025 at 8:09 PM
Straight from #UromigosLive 2025
A GREAT discussion on ADC use in #BladderCancer
The possibility of Combination Trials, seeing the trade off between Toxicity and the Long Term Benefit
Complete Video Here x.com/Uromigos/sta...
A GREAT discussion on ADC use in #BladderCancer
The possibility of Combination Trials, seeing the trade off between Toxicity and the Long Term Benefit
Complete Video Here x.com/Uromigos/sta...
Here at #UromigosLive 2025 in Nashville and have the pleasure to have the Uromigos discuss Combinations in Heavily Treated #KidneyCancer Patients
Tom wonders if it is time to say that this second generation check points have not been that impressive
Give them a quick listen
buff.ly/EV0pcsN
Tom wonders if it is time to say that this second generation check points have not been that impressive
Give them a quick listen
buff.ly/EV0pcsN
Uromigos (@Uromigos) on X
A Great First Day of #UromigosLive 2025🇺🇸 On our Out and about in Nashville Series, @tompowles1 and @brian_rini Discuss #KidneyCancer Combination Treatments and give us a little history on the…
buff.ly
November 8, 2025 at 5:30 PM
Here at #UromigosLive 2025 in Nashville and have the pleasure to have the Uromigos discuss Combinations in Heavily Treated #KidneyCancer Patients
Tom wonders if it is time to say that this second generation check points have not been that impressive
Give them a quick listen
buff.ly/EV0pcsN
Tom wonders if it is time to say that this second generation check points have not been that impressive
Give them a quick listen
buff.ly/EV0pcsN
Here at #UromigosLive 2025 in Nashville and have the pleasure to have the @Uromigos Tom and Briandiscuss Combinations in Heavily Treated #KidneyCancer
Here they KEYMAKER U03 in KidneyCancer
Give them a quick listen and if you want to dive deeper, here is the full video
buff.ly/EV0pcsN
Here they KEYMAKER U03 in KidneyCancer
Give them a quick listen and if you want to dive deeper, here is the full video
buff.ly/EV0pcsN
Uromigos (@Uromigos) on X
A Great First Day of #UromigosLive 2025🇺🇸 On our Out and about in Nashville Series, @tompowles1 and @brian_rini Discuss #KidneyCancer Combination Treatments and give us a little history on the…
buff.ly
November 8, 2025 at 3:00 PM
Here at #UromigosLive 2025 in Nashville and have the pleasure to have the @Uromigos Tom and Briandiscuss Combinations in Heavily Treated #KidneyCancer
Here they KEYMAKER U03 in KidneyCancer
Give them a quick listen and if you want to dive deeper, here is the full video
buff.ly/EV0pcsN
Here they KEYMAKER U03 in KidneyCancer
Give them a quick listen and if you want to dive deeper, here is the full video
buff.ly/EV0pcsN
Here at #UromigosLive 2025 in Nashville and have the pleasure to have the @Uromigos @tompowles1 and @brian_rini discuss Combinations in Heavily Treated #KidneyCancer Patients
Give them a quick listen and if you want to dive deeper, here is the full video
Give them a quick listen and if you want to dive deeper, here is the full video
Uromigos Live 2025 Kidney Cancer Combination Treatments
During the #UromigosLive Meeting and in our walking through Nashville Series, Dr. Brian Rini and Dr. Tom Powles give us a breakdown of #kidneycancer Combination Treatments and a little bit of…
youtu.be
November 8, 2025 at 1:45 PM
Here at #UromigosLive 2025 in Nashville and have the pleasure to have the @Uromigos @tompowles1 and @brian_rini discuss Combinations in Heavily Treated #KidneyCancer Patients
Give them a quick listen and if you want to dive deeper, here is the full video
Give them a quick listen and if you want to dive deeper, here is the full video
Uromigos Live 2025 Kidney Cancer Combination Treatments with Brian Rini and Tom Powles on our Out and about in Nashville Series WATCH HERE 👉 youtu.be/_blk6T4HFOk
Uromigos Live 2025 Kidney Cancer Combination Treatments
During the #UromigosLive Meeting and in our walking through Nashville Series, Dr. Brian Rini and Dr. Tom Powles give us a breakdown of #kidneycancer Combination Treatments and a little bit of…
youtu.be
November 7, 2025 at 9:21 PM
Uromigos Live 2025 Kidney Cancer Combination Treatments with Brian Rini and Tom Powles on our Out and about in Nashville Series WATCH HERE 👉 youtu.be/_blk6T4HFOk